Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) was consistently greater with incubation periods of 182-hours compared to 96-hours (Figure 6 and Figure 7). This evidence concerns the gene EGFR and breast adenocarcinoma.